White House indefinitely postpones Trump's speech on lowering drug prices

President Donald Trump has postponed this week’s speech on battling rising prescription drug costs, according to the White House. No future date, time or location has been announced for the speech, previously scheduled for Thursday, April 26.

Trump made high drug prices a major issue in his campaign for president, saying pharmaceutical companies are “getting away with murder” and has promised to tackle such rising costs.

The speech, despite some speculation it would be harsh on pharmaceutical companies, included relatively small steps in battling increased costs. Trump was expected to outline three major actions:

  • HHS will issue for a request for information on drug price policies.
  • CMS will alter its drug pricing dashboard, with the proposal being called a “shaming tool” by an Axios source.
  • The FDA will continue efforts on expanding the availability of generics.
""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.